286 related articles for article (PubMed ID: 33519816)
1. CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01.
Bosteels C; Fierens K; De Prijck S; Van Moorleghem J; Vanheerswynghels M; De Wolf C; Chalon A; Collignon C; Hammad H; Didierlaurent AM; Lambrecht BN
Front Immunol; 2020; 11():606805. PubMed ID: 33519816
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant system AS01: helping to overcome the challenges of modern vaccines.
Didierlaurent AM; Laupèze B; Di Pasquale A; Hergli N; Collignon C; Garçon N
Expert Rev Vaccines; 2017 Jan; 16(1):55-63. PubMed ID: 27448771
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 4 signaling in hematopoietic-lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01.
Van Maele L; Fougeron D; Cayet D; Chalon A; Piccioli D; Collignon C; Sirard JC; Didierlaurent AM
Eur J Immunol; 2019 Dec; 49(12):2134-2145. PubMed ID: 31489613
[TBL] [Abstract][Full Text] [Related]
5. Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review.
Lacaille-Dubois MA
Phytomedicine; 2019 Jul; 60():152905. PubMed ID: 31182297
[TBL] [Abstract][Full Text] [Related]
6. Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine.
Fochesato M; Dendouga N; Boxus M
Hum Vaccin Immunother; 2016 Aug; 12(8):2092-2095. PubMed ID: 26933767
[TBL] [Abstract][Full Text] [Related]
7. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
[TBL] [Abstract][Full Text] [Related]
8. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.
Marty-Roix R; Vladimer GI; Pouliot K; Weng D; Buglione-Corbett R; West K; MacMicking JD; Chee JD; Wang S; Lu S; Lien E
J Biol Chem; 2016 Jan; 291(3):1123-36. PubMed ID: 26555265
[TBL] [Abstract][Full Text] [Related]
9. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice.
Dendouga N; Fochesato M; Lockman L; Mossman S; Giannini SL
Vaccine; 2012 Apr; 30(20):3126-35. PubMed ID: 22326899
[TBL] [Abstract][Full Text] [Related]
10. Saponin-based adjuvants enhance antigen cross-presentation in human CD11c
Ho NI; Huis In 't Veld LGM; van Eck van der Sluijs J; Heuts BMH; Looman MWG; Kers-Rebel ED; van den Dries K; Dolstra H; Martens JHA; Hobo W; Adema GJ
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612044
[TBL] [Abstract][Full Text] [Related]
11. CCR2 Regulates Vaccine-Induced Mucosal T-Cell Memory to Influenza A Virus.
Lee W; Kingstad-Bakke B; Kedl RM; Kawaoka Y; Suresh M
J Virol; 2021 Jul; 95(15):e0053021. PubMed ID: 33952647
[TBL] [Abstract][Full Text] [Related]
12. The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.
Schmidt ST; Khadke S; Korsholm KS; Perrie Y; Rades T; Andersen P; Foged C; Christensen D
J Control Release; 2016 Oct; 239():107-17. PubMed ID: 27574990
[TBL] [Abstract][Full Text] [Related]
13. Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice.
Wui SR; Kim KS; Ryu JI; Ko A; Do HTT; Lee YJ; Kim HJ; Lim SJ; Park SA; Cho YJ; Kim CG; Lee NG
Vaccine; 2019 Apr; 37(15):2131-2141. PubMed ID: 30827737
[TBL] [Abstract][Full Text] [Related]
14. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8
Matsuo K; Kitahata K; Kawabata F; Kamei M; Hara Y; Takamura S; Oiso N; Kawada A; Yoshie O; Nakayama T
Front Immunol; 2018; 9():2775. PubMed ID: 30542351
[TBL] [Abstract][Full Text] [Related]
15. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection.
Bosteels C; Neyt K; Vanheerswynghels M; van Helden MJ; Sichien D; Debeuf N; De Prijck S; Bosteels V; Vandamme N; Martens L; Saeys Y; Louagie E; Lesage M; Williams DL; Tang SC; Mayer JU; Ronchese F; Scott CL; Hammad H; Guilliams M; Lambrecht BN
Immunity; 2020 Jun; 52(6):1039-1056.e9. PubMed ID: 32392463
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
18. A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.
Xiao L; Kim J; Lim M; Dai B; Yang L; Reed SG; Baltimore D; Wang P
Vaccine; 2012 Mar; 30(15):2570-81. PubMed ID: 22314134
[TBL] [Abstract][Full Text] [Related]
19. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
